CTLA 4 News and Research

RSS

Engineered extracellular vesicles enable antigen-specific regulatory T cell induction

A research team at the Nano Life Science Institute (WPI-NanoLSI) and the Faculty of Medicine at Kanazawa University has developed a new class of engineered extracellular vesicles (EVs) capable of inducing antigen-specific regulatory T cells (Tregs), the immune cells that play a central role in suppressing excessive immune responses.

22 Dec 2025

AI-guided discovery of selective DGKα inhibitors to overcome checkpoint resistance in solid cancers

Insilico Medicine has developed a new class of small molecule inhibitors targeting diacylglycerol kinase alpha (DGKα) designed to restore T cell function and overcome resistance to immune checkpoint blockades in solid cancers.

12 Dec 2025

Enhancing the cancer-immunity cycle through innovative vaccines

Therapeutic cancer vaccines have experienced a remarkable resurgence over the past decade, representing a paradigm shift in oncology toward harnessing the immune system's intrinsic ability to combat malignancies.

14 Nov 2025

Rapamycin shows promise in treating cold tumors with specific gene mutation

Immune checkpoint inhibitors (ICIs) emerged in the US about 15 years ago as an exciting class of cancer treatments that have achieved complete and durable remissions for thousands of people with end-stage metastatic cancers.

29 Oct 2025

UCSF team uncovers breakthrough immunotherapy for colon cancer liver metastases

Advanced colon cancer is the leading cause of cancer-related death in young American men and the second highest worldwide. In the majority of these patients, as the cancer advances it metastasizes to the liver.

8 Oct 2025

Scientists outline how future therapies could change type 1 diabetes care

Researchers writing in The Lancet review breakthroughs in type 1 diabetes treatment, from immunotherapies that delay onset to stem-cell β-cell replacement and automated insulin delivery. They stress that equitable access, validated surrogate endpoints, and scalable technologies are crucial for lasting impact.

24 Sep 2025

Study identifies immune biomarkers for personalized therapies in pediatric germ cell tumors

A study conducted by the Molecular Oncology Research Center (CPOM) at Hospital de Amor in Barretos (formerly Barretos Cancer Hospital) in the state of São Paulo, Brazil, has identified possible biomarkers that could guide the development of more personalized therapies for pediatric germ cell tumors (GCTs).

18 Sep 2025

Exosomes play a dual role in cancer progression and immune regulation

Tiny extracellular vesicles known as exosomes are emerging as key regulators of the tumor microenvironment (TME), influencing how cancer progresses, spreads, and responds to treatment.

7 Aug 2025

Targeting lactate metabolism offers new avenues for cancer treatment

Lactic acid (LA) has transitioned from being perceived as a mere glycolytic waste product to a pivotal regulator of tumor-immune crosstalk.

5 Aug 2025

Gfi1 regulates exhausted CD8+ T cells to improve cancer immunotherapy

Killer immune cells destroy cancer cells and cells infected by virus. These CD8+ T cells are activated after detection of viral infection or growth of "non-self" tumor cells.

5 Aug 2025

Cancer immunotherapies linked to increased risk of liver cholestasis

A global study reveals that cutting-edge cancer immunotherapies, while lifesaving, carry a hidden risk: they may trigger cholestasis, a serious liver condition where bile flow stalls.

30 Jul 2025

Reversing immune fatigue offers new hope for cancer treatment

CD8⁺ T cells are the immune system's frontline warriors, charged with detecting and eliminating cancer cells. But in the hostile and chronic environment of tumors, these cells often falter.

7 Jul 2025

XPR1 silencing enhances immune response and reduces ovarian tumor growth

A recent study published in Genes & Diseases reveals a novel role of XPR1 in promoting ovarian cancer growth by regulating autophagy and MHC-I expression.

4 Jul 2025

Immune changes predict heart risks in cancer patients on checkpoint inhibitors

New research has uncovered immune changes in cancer patients that could help identify which patients are most at risk of dangerous heart complications from cancer drugs, known as immune checkpoint inhibitors.

20 Jun 2025

Rare pancreatic cancer patients show remarkable outcomes with immunotherapy

A new research paper was published in Volume 16 of Oncotarget on June 10, 2025, titled "Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence."

17 Jun 2025

Immune microRNAs drive new frontiers in cardiovascular disease research

Cardiovascular diseases (CVDs) continue to dominate global mortality statistics, with immune dysregulation emerging as a central feature in their pathogenesis.

28 May 2025

Targeting MARCO enhances cancer immunotherapy effectiveness

Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO.

13 Mar 2025

Combination immunotherapy improves treatment response for head and neck cancer

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs) found that patients responded better to a combination of two immunotherapies than patients who received just one immunotherapy drug.

13 Mar 2025

Radiation and immunotherapy help preserve bladders in patients with muscle-invasive bladder cancer

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses that allowed for bladder preservation, according to results from the IMMUNOPRESERVE clinical trial.

18 Feb 2025

Microbes in your gut could determine cancer treatment outcomes

Researchers reveal that gut microbiota influence the effectiveness of immune checkpoint inhibitors (ICIs) in cancer treatment, with specific bacterial strains enhancing or inhibiting anti-tumor immunity.

4 Feb 2025